Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Diabetes data validates AVI BioPharma technology
The study demonstrated the effectiveness of AVI’s exon skipping technology in significantly delaying the onset of diabetes and in reversing the disease after onset. This work validates the
The study demonstrated the effectiveness of AVI’s exon skipping technology in significantly delaying the onset of diabetes and in reversing the disease after onset. This work validates the
The deal represents the second major collaboration for Genelabs based on its hepatitis C virus (HCV) drug delivery platform. Under the terms of the agreement, Genelabs is eligible
At the American Society of Clinical Oncology (ASCO) meeting, Pfizer presented data from a trial evaluating Aromasin in breast cancer and from several trials investigating Sutent in a
The primary objective of the first phase III trial, named DORADO, is to determine if darusentan is effective in reducing systolic blood pressure in resistant hypertension patients currently
Petition requested FDA to require all in vitro diagnostic tests intended for use in drug or biologic therapeutic decision-making to be held to the same scientific and regulatory
Designated as TF3 and TF5, the new bispecific constructs were created using the Dock and Lock (DNL) method recently published in the Proceedings of the National Academy of
The data, presented in two abstracts at the American Society of Gene Therapy (ASGT) 2006 Annual Meeting, demonstrate that adeno-associated virus type 2 (AAV2), the delivery vector used
The phase I study assessed dose-limiting toxicities, maximum tolerated dose, and pharmacokinetics of AN-152 given once every three weeks in patients with gynaecological and breast cancers. Eight patients
In the study, which was designed to evaluate the efficacy of an oral formulation of SCV-07 in tuberculosis (TB), mice were infected with M. tuberculosis Erdman. Twelve days
Under the agreement, Glenmark will be responsible for preclinical development, will manage the clinical trials and manufacture the products; Glenmark will be responsible for filing the abbreviated new